

1646

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1242)

RECEIVED

In the Application of:

Ward, et al.

Serial No.: 09/936,964

Filing Date: March 15, 2000

For: Anti-p53 Antibodies

MAR 12 2003

Examiner: TBA

TECH CENTER 1600/2900

Group Art Unit: 1646

Confirmation No.: 4441

TRANSMITTAL LETTER


Commissioner for Patents
Washington, D.C. 20231

Dear Sir:

In regard to the above identified application,

1. We are transmitting herewith the attached:
 - a) Information Disclosure Statement;
 - b) PTO Form 1449 and 22 references cited therein; and
 - c) return receipt postcard.
2. With respect to fees:
 - a) A fee is not required at this time.
 - b) Please charge any underpayment or credit any overpayment our Deposit Account, No. 13-2490.
3. CERTIFICATE OF MAILING UNDER 37 CFR § 1.8: The undersigned hereby certifies that this Transmittal Letter and the paper, as described in paragraph 1, are being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to Commissioner for Patents, Washington, D.C. 20231 on March 5, 2003.

Respectfully submitted,



Michael S. Greenfield
Registration No. 37,142

Date: March 5, 2003



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Case No. 01-1242)

6/11/03
PATENT
RECEIVED

In the Application of:

Ward, et al.

Serial No.: 09/936,964

Filing Date: March 15, 2000

For: Anti-p53 Antibodies

) Examiner: TBA

) Group Art Unit: 1646

) Confirmation No.: 4441

MAR 12 2003

TECH CENTER 1600/2900

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of Patents and Trademarks
Washington, D.C. 20231

Dear Sir:

Pursuant to 37 C.F.R. Section 1.97 - 1.99, the Applicant wishes to make the following references of record in the above-identified application. This Information Disclosure Statement is in compliance with the continuing duty of candor as set forth in 37 C.F.R. Section 1.56. Copies of the cited references are enclosed. These references are also listed on the enclosed PTO Form 1449.

This statement is not a representation that the listed references have effective dates early enough to be "prior art" within the meaning of 35 U.S.C. Section 102 or Section 103.

Applicants do not believe any fee is due with this submission. If this belief be in error and the Patent Office determines that the fee prescribed in the relevant portion of 37 C.F.R. Section 1.97 is applicable, the undersigned attorney by his signature hereby authorizes any such fee to be debited from Deposit Account 13-2490.

FOREIGN PATENT DOCUMENTS

1. WO 98/15834 16 April 1998 PCT

CERTIFICATE OF MAILING (37 C.F.R. 1.8a)

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to the: Commissioner for Patents, Washington D.C. 20231, on March 5, 2003.

Date: March 5, 2003

Michael S. Greenfield


OTHER DOCUMENTS

2. Ko, Linda J. and Prives, Carol, "p53: Puzzle and Paradigm," Department of Biological Sciences, Columbia University, New York 10027 USA, Genes and Development 10: 1054-1072 (1996).
3. Soussi, Thierry and May, Pierre, "Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look," *J. Mol. Biol.* (1996) 260, 623-637.
4. Lubin, et al., "Analysis of p53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p53: Distribution of Primary Structure and Exposure on Protein Surface," 5872-5876, December 15, 1993.
5. Computer Corner, "Methods and Reagents, Fidelity of DNA polymerases for PCR," TIBS 20 – August 1995.
6. Nissim, et al., "Antibody Fragments from a 'Single Pot' Phage Display Library as Immunochemical Reagents," *The EMBO Journal*, vol. 13, no. 3, pp. 692-698 (1994).
7. Chang, Bernard and Casali, Paolo, "The CDR1 Sequences of a Major Proportion of Human Germline Ig V_H Genes are Inherently Susceptible to Amino Acid Replacement," *Innunogolgy Today*, Vol. 15, No. 8 (1994).
8. Clark, et al., "Isolation of Human anti-c-erbB-2 Fabs from a Lymph Node-Derived Phage display library," *Clin Exp Immunol* 109: 166-174 (1997).
9. Ward, et al., "Retrieval of Human Antibodies from Phage-Display Libraries Using Enzymatic Cleavage," *Journal of Immunological Methods* 189 (1996) 73-82.
10. Chomczynski, Piotr and Sacchi, Nicoletta, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Choloroform Extraction," *Analytical Biochemistry* 16, 158-159 (1987).
11. Coomber, et. al., "Characterisation and Clinicopathological Correlates of Serum Anti-p53 Antibodies in Breast and Colon Cancer," *J Cancer Res Clin Oncol* (1996) 122: 757-762.
12. Abrams, et al., "Optimal Strategies for Developing Human-Human Monoclonal Antibodies," *Methods in Enzymology*, vol. 121 (1986).
13. Winter, et al., "Development of Antibodies against p53 in Lung Cancer Patients Appears To Be Dependent on the Type of p53 Mutation," *Cancer Research* 52, 4168-4174, August 1, 1992.
14. Vogelstein, Bert and Kinzler, Kenneth W., "p53 Function and Dysfunction," *Cell*, Vol. 70, 532-526, August 21, 1992.
15. Hollstein, et al., "p53 Mutations in Human Cancers," *Science*, vol. 253, 5 July 1991.
16. Pavletich, et al., "The DNA-Binding Domain of p53 Contains the Four Conserved Regions and the Major Mutation Hot Spots," *Genes and Development* 7:2556-2564, 1993.
17. Smith, George P., "Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Viron Surface.
18. Nagesha, et al., "Application of linker-ligation-PCR for Construction of Phage Display Epitope Libraries," *Journal of Virological Methods* 60 (1996) 147-154.

19. Petersen, et al., "Mapping of Linear Epitopes Recognized by Monoclonal Antibodies with Gene-Fragment Phage Display Libraries," *Gen Genet* (1995) 249: 425-431.
20. Welschof, et al., "The Antigen-Binding Domain of a Human IgG-Anti F(ab')₂ Autoantibody," *Proc. Natl. Acad. Sci. USA* Vol. 94, pp. 1902-1907, March 1997 *Immunology*.
21. Database Swiss-Prot, accession number P01625, 21 July 1996.
22. Database PIR, accession number s58207, 13 January 1996.

Respectfully submitted,
McDonnell Boehnen Hulbert & Berghoff

By:


Michael S. Greenfield
Reg. No. 37,142

Date: March 5, 2003

Telephone: 312-913-0001
Facsimile: 312-913-0002

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive, 32nd Floor
Chicago, IL 60606

FORM PTO-1449
(Rev. 2-32)

U.S. Department of Commerce
Patent and Trademark Office

Atty. Docket No.

01-1242

Serial No.

09/936,964



**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**
(Use several sheets if necessary)

Applicant:

Ward, et al.

Filing Date:

March 15, 2000

Group:

1646

U.S. PATENT DOCUMENTS

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate

FOREIGN PATENT DOCUMENTS

		Document Number	Date	Country	Class	Subclass	Translation
							Yes
							No
1.		WO 98/15834	16 April 1998	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).

2.	Ko, Linda J. and Prives, Carol, "p53: Puzzle and Paradigm," Department of Biological Sciences, Columbia University, New York 10027 USA, Genes and Development 10: 1054-1072 (1996).
3.	Soussi, Thierry and May, Pierre, "Structural Aspects of the p53 Protein in Relation to Gene Evolution: A Second Look," J. Mol. Biol. (1996) 260, 623-637.
4.	Lubin, et al., "Analysis of p53 Antibodies in Patients with Various Cancers Define B-Cell Epitopes of Human p53: Distribution of Primary Structure and Exposure on Protein Surface," 5872-5876, December 15, 1993.
5.	Computer Corner, "Methods and Reagents, Fidelity of DNA polymerases for PCR," TIBS 20 - August 1995.
6.	Nissim, et al., "Antibody Fragments from a 'Single Pot' Phage Display Library as Immunochemical Reagents," The EMBO Journal, vol. 13, no. 3, pp. 692-698 (1994).
7.	Chang, Bernard and Casali, Paolo, "The CDR1 Sequences of a Major Proportion of Human Germline Ig V _H

		Genes are Inherently Susceptible to Amino Acid Replacement," <i>Inmunogolgy Today</i> , Vol. 15, No. 8 (1994).
	8.	Clark, et al., "Isolation of Human anti-c-erbB-2 Fabs from a Lymph Node-Derived Phage display library," <i>Clin Exp Immunol</i> 109: 166-174 (1997).
	9.	Ward, et al., "Retrieval of Human Antibodies from Phage-Display Libraries Using Enzymatic Cleavage," <i>Journal of Immunological Methods</i> 189 (1996) 73-82.
	10.	Chomczynski, Piotr and Sacchi, Nicoletta, "Single-Step Method of RNA Isolation by Acid Guanidinium Thiocyanate-Phenol-Choloroform Extraction," <i>Analytical Biochemistry</i> 16, 158-159 (1987).
	11.	Coomber, et. al., "Characterisation and Clinicopathological Correlates of Serum Anti-p53 Antibodies in Breast and Colon Cancer," <i>J Cancer Res Clin Oncol</i> (1996) 122: 757-762.
	12.	Abrams, et al., "Optimal Strategies for Developing Human-Human Monoclonal Antibodies," <i>Methods in Enzymology</i> , vol. 121 (1986).
	13.	Winter, et al., "Development of Antibodies against p53 in Lung Cancer Patients Appears To Be Dependent on the Type of p53 Mutation," <i>Cancer Research</i> 52, 4168-4174, August 1, 1992.
	14.	Vogelstein, Bert and Kinzler, Kenneth W., "p53 Function and Dysfunction," <i>Cell</i> , Vol. 70, 532-526, August 21, 1992.
	15.	Hollstein, et al., "p53 Mutations in Human Cancers," <i>Science</i> , vol. 253, 5 July 1991.
	16.	Pavletich, et al., "The DNA-Binding Domain of p53 Contains the Four Conserved Regions and the Major Mutation Hot Spots," <i>Genes and Development</i> 7:2556-2564, 1993.
	17.	Smith, George P., "Filamentous Fusion Phage: Novel Expression Vectors that Display Cloned Antigens on the Viron Surface.
	18.	Nagesha, et al., "Application of linker-ligation-PCR for Construction of Phage Display Epitope Libraries," <i>Journal of Virological Methods</i> 60 (1996) 147-154.
	19.	Petersen, et al., "Mapping of Linear Epitopes Recognized by Monoclonal Antibodies with Gene-Fragment Phage Display Libraries," <i>Gen Genet</i> (1995) 249: 425-431.
	20.	Welschof, et al., "The Antigen-Binding Domain of a Human IgG-Anti F(ab') ₂ Autoantibody," <i>Proc. Natl. Acad. Sci. USA</i> Vol. 94, pp. 1902-1907, March 1997 <i>Immunology</i> .
	21.	Database Swiss-Prot, accession number P01625, 21 July 1996.
	22.	Database PIR, accession number s58207, 13 January 1996.
EXAMINER		DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.